Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3410738 in Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label trial of crelosidenib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 30 months and Overall Response Rate at 30 months. Started Nov 2020; status: active, not recruiting.
02
Drugs
crelosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT04603001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603001.